Initial study results indicate that patients undergoing the InSpace™ procedure for the surgical treatment of massive rotator cuff tears experienced durable improvements in shoulder function and reductions in shoulder pain at 12 months, suggesting that InSpace is an effective alternative to existing surgical treatments.
InSpace comprises a biodegradable balloon spacer that is implanted in the subacromial space in a procedure that may be performed arthroscopically or under fluoroscopic guidance.
The two-year study will enroll up to 45 elderly patients who are not candidates for surgery under general anesthesia and who did not respond to conservative treatment, including steroid injections and physical therapy.
OrthoSpace just closed a US $7MM equity financing round in support of an ongoing U.S. Investigational Device Exemption study, as well as commercialization activity in Asia, Europe and South America.
Initial study results indicate that patients undergoing the InSpace™ procedure for the surgical treatment of massive rotator cuff tears experienced durable improvements in shoulder function and reductions in shoulder pain at 12 months, suggesting that InSpace is an effective alternative to existing surgical treatments.
InSpace comprises a...
Initial study results indicate that patients undergoing the InSpace™ procedure for the surgical treatment of massive rotator cuff tears experienced durable improvements in shoulder function and reductions in shoulder pain at 12 months, suggesting that InSpace is an effective alternative to existing surgical treatments.
InSpace comprises a biodegradable balloon spacer that is implanted in the subacromial space in a procedure that may be performed arthroscopically or under fluoroscopic guidance.
The two-year study will enroll up to 45 elderly patients who are not candidates for surgery under general anesthesia and who did not respond to conservative treatment, including steroid injections and physical therapy.
OrthoSpace just closed a US $7MM equity financing round in support of an ongoing U.S. Investigational Device Exemption study, as well as commercialization activity in Asia, Europe and South America.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
